Get started
Author

Seigo Akari

ORCID: 0000-0001-6641-1062
Observed ORCID: 0000-0001-6641-1062
OpenAlex ID: A5039283556
Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry
2021 · Masafumi Kurajoh, Shinya Fukumoto, et al. · Scientific Reports · 124
PDF
Increased plasma XOR activity induced by NAFLD/NASH and its possible involvement in vascular neointimal proliferation
2021 · Yusuke Kawachi, Yuya Fujishima, et al. · JCI Insight · 30
PDF
Independent association of plasma xanthine oxidoreductase activity with hypertension in nondiabetic subjects not using medication
2021 · Masato Furuhashi, Yukimura Higashiura, et al. · Hypertension Research · 17
Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees
2022 · Masafumi Kurajoh, Shinya Fukumoto, et al. · Scientific Reports · 11
PDF
Xanthine oxidoreductase activity in marathon runners: potential implications for marathon-induced acute kidney injury
2022 · Keisei Kosaki, Shota Kumamoto, et al. · Journal of Applied Physiology · 11
Influence of xanthine oxidoreductase inhibitor, topiroxostat, on body weight of diabetic obese mice
2021 · Takashi Nakamura, Mai Nampei, et al. · Nutrition and Diabetes · 11
PDF
Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment
2020 · Yusuke Kawachi, Yuya Fujishima, et al. · Journal of Diabetes Investigation · 11
PDF
The reality of treatment for hyperuricemia and gout in Japan: A historical cohort study using health insurance claims data
2022 · Seigo Akari, Takashi Nakamura, et al. · Journal of Clinical Hypertension · 8
Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight
2020 · Yuichi Saito, Naoto Mori, et al. · Heart and Vessels · 8
The Effects of Topiroxostat, a Selective Xanthine Oxidoreductase Inhibitor, on Arterial Stiffness in Hyperuricemic Patients with Liver Dysfunction: A Sub-Analysis of the BEYOND-UA Study
2023 · Yuya Fujishima, Hitoshi Nishizawa, et al. · Biomedicines · 7
PDF
Cardiovascular Events During Treatment With Xanthine Oxidoreductase Inhibitors in Patients With Gout and Hyperuricemia in Japan ― A JMDC Claims Database Study ―
2025 · Kazuomi Kario, Seigo Akari, et al. · Circulation Reports · 6
PDF
Seasonal variations for newly prescribed urate-lowering drugs for asymptomatic hyperuricemia and gout in Japan
2024 · Masafumi Kurajoh, Seigo Akari, et al. · Frontiers in Pharmacology · 5
PDF
Association of plasma xanthine oxidoreductase activity with vascular endothelial function independent of serum uric acid level: MedCity21 health examination registry
2023 · Masafumi Kurajoh, Shinya Fukumoto, et al. · IJC Heart & Vasculature · 4
Upacicalcet Preserves Albumin Levels in Patients on Hemodialysis with Secondary Hyperparathyroidism: A post hoc Analysis of a Randomized Trial
2025 · Hirotaka Komaba, Seigo Akari, et al. · American Journal of Nephrology · 2
PDF
Plasma xanthine oxidoreductase is associated with carotid atherosclerosis in stable kidney transplant recipients
2021 · Rikako Oki, Yoshifumi Hamasaki, et al. · Nephrology · 2
Upacicalcet: A Novel Intravenous Calcimimetic Agent for Patients Undergoing Hemodialysis With Secondary Hyperparathyroidism
2026 · Fumihiko Koiwa, Daisuke Honda, et al. · Therapeutic Apheresis and Dialysis · 1
PDF
Associations between muscle quality and whole-body vibration exercise-induced changes in plasma hypoxanthine following an oral glucose load in healthy male subjects
2024 · Tomoyuki Hara, Yuya Fujishima, et al. · Endocrine Journal · 1
PDF
Associations of circulating xanthine oxidoreductase activity with cardiometabolic risk markers in overweight and obese Japanese men: a cross-sectional pilot study
2022 · Keisei Kosaki, Atsumu Yokota, et al. · Journal of Clinical Biochemistry and Nutrition · 1
PDF
Evidence for PTH-Independent Effects of Upacicalcet on Bone Metabolism: A Mediation Analysis
2026 · Suguru Yamamoto, Hisami Yasuzawa, et al. · Journal of the American Society of Nephrology
Phase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults
2026 · Fumio Otsuka, Keiko Hanabara, et al. · Clinical Pharmacology in Drug Development
Elastin calcification during the initial stage of vascular calcification in kl/kl mice is suppressed by the calcimimetic upacicalcet
2026 · Tomoka Hasegawa, Tomomaya Yamamoto, et al. · Scientific Reports
#773 Upacicalcet preserves albumin levels in hemodialysis patients with secondary hyperparathyroidism: a post-hoc analysis of a randomized trial
2025 · Hirotaka Komaba, Seigo Akari, et al. · Nephrology Dialysis Transplantation
PDF
Association of hepatic steatosis with increased plasma xanthine oxidoreductase activity: MedCity21 health examination registry
2025 · Masafumi Kurajoh, Shinya Fukumoto, et al. · Metabolism Open
Pharmacological properties and clinical trial results of the novel calcium-sensing receptor agonist upacicalcet sodium hydrate (Upacita® intravenous injection for dialysis)
2025 · Takeju Otsuki, Seigo Akari, et al. · Folia Pharmacologica Japonica
Systemic Endothelial Function, Plasma Xanthine Oxidoreductase Activity, and Blood Pressure Variability in Patients with Stable Coronary Artery Disease
2022 · Takashi Hiraga, Yuichi Saito, et al. · Medicina
PDF
Works count: 26
Citation count: 260
H-index: 8
I10-index: 7
Year
Topic
Type